Valuation: Adimmune Corporation

Market Cap 7.08B 219M 191M 176M 162M 306M 21.06B 314M 2.11B 828M 10.31B 822M 804M 35.52B P/E 2024
-34.7x
P/E 2025 -33.2x
Enterprise Value 7.69B 238M 208M 192M 176M 333M 22.88B 341M 2.29B 900M 11.2B 893M 873M 38.59B EV / Sales 2024
5.53x
EV / Sales 2025 6.14x
Free-Float
70.19%
Yield 2024 *
-
Yield 2025 -
1 day-3.17%
1 week-4.82%
Current month-4.55%
1 month-3.72%
3 months-10.16%
6 months-18.05%
Current year-11.35%
1 week 16.65
Extreme 16.65
17.55
1 month 16.65
Extreme 16.65
18.2
Current year 16.65
Extreme 16.65
21.5
1 year 16.65
Extreme 16.65
22.5
3 years 15.9
Extreme 15.9
38
5 years 15.9
Extreme 15.9
56.2
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 20/06/2019
Director of Finance/CFO - 01/01/2021
Chief Tech/Sci/R&D Officer - 26/01/2022
Director TitleAgeSince
Director/Board Member 72 20/06/2019
Director/Board Member - 15/08/2011
Chairman - 01/07/2008
Change 5-day change 1-year change 3-year change Capi.($)
-3.17%-4.82%-2.33%-52.54% 227M
-0.33%+1.31%+23.50%-5.82% 69.07B
+0.67%-4.28%+41.06%+201.69% 51.77B
+0.94%+39.60%+39.60%+39.60% 43.63B
+1.12%-1.76%-50.16%-52.75% 40.89B
-1.40%+3.56%+60.35%-26.15% 30.84B
-2.11%-19.25%+92.83%-49.06% 25.06B
+0.51%-1.07%+69.36%+89.85% 23.3B
-5.57%+3.01%+3.19%+174.11% 20.92B
-0.86%-3.55%+63.18%+127.04% 16.71B
Average -1.02%-1.55%+34.06%+44.60% 32.24B
Weighted average by Cap. -0.36%-1.35%+32.10%+47.83%

Financials

2024 2025
Net sales 1.56B 48.11M 42.01M 38.79M 35.7M 67.35M 4.63B 68.95M 463M 182M 2.27B 181M 177M 7.81B 1.4B 43.3M 37.81M 34.91M 32.14M 60.63M 4.17B 62.07M 417M 164M 2.04B 163M 159M 7.03B
Net income -243M -7.5M -6.55M -6.05M -5.57M -10.5M -722M -10.75M -72.26M -28.39M -353M -28.17M -27.55M -1.22B -240M -7.41M -6.47M -5.98M -5.5M -10.38M -714M -10.62M -71.41M -28.06M -349M -27.84M -27.22M -1.2B
Net Debt 140M 4.31M 3.77M 3.48M 3.2M 6.04M 415M 6.18M 41.54M 16.32M 203M 16.19M 15.84M 700M 612M 18.92M 16.52M 15.25M 14.04M 26.49M 1.82B 27.12M 182M 71.61M 891M 71.05M 69.48M 3.07B
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
17/07/26 NT$16.80 -3.17% 1,458,918
16/07/26 NT$17.35 -0.57% 622,174
15/07/26 NT$17.45 +3.56% 1,422,965
14/07/26 NT$16.85 -1.17% 1,554,261
13/07/26 NT$17.05 -3.40% 2,324,953
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock